Vaginal Pap Testing After Hysterectomy for Adenocarcinoma In Situ

Initial Intensive Surveillance Phase

Women who undergo hysterectomy for adenocarcinoma in situ require extended vaginal cytology surveillance for 20-25 years post-hysterectomy, regardless of age at completion of this period, as recommended by the CDC and other guideline societies 1, 2
The American College of Obstetricians and Gynecologists recommends beginning vaginal cytology screening every 4-6 months immediately after hysterectomy until three consecutive, technically satisfactory normal/negative results are achieved within an 18-24 month period 2, 3
Adenocarcinoma in situ has unique characteristics that increase recurrence risk, including being frequently multifocal, having "skip lesions", and extending deep into the endocervical canal, making complete excision difficult even with negative margins 4, 5

After achieving three consecutive normal results, transition to annual vaginal cytology for a minimum of 20-25 years from the date of hysterectomy, as recommended by the CDC and other guideline societies 1, 2, 3
The American College of Obstetricians and Gynecologists recommends continuing screening indefinitely as long as the patient remains in reasonably good health without life-limiting chronic conditions—there is no upper age limit for discontinuation 2, 3

The American College of Obstetricians and Gynecologists explicitly states that adenocarcinoma in situ is not a benign indication for hysterectomy, and women with AIS history fall into the same high-risk category as those with invasive cervical cancer or CIN2/3, requiring decades of surveillance 2, 6, 7
The CDC guidelines specifically state that persons who had total hysterectomy with cervix removal do not require screening unless CIN2, CIN3, or adenocarcinoma in situ was diagnosed within the previous 20 years 1

Women with adenocarcinoma in situ history have significantly increased risk for vaginal intraepithelial neoplasia and vaginal cancer compared to the general population 2
Even with negative margins on hysterectomy specimens, residual disease can remain due to the multifocal nature and skip lesions characteristic of adenocarcinoma in situ 4

Never apply average-risk screening cessation guidelines to adenocarcinoma in situ patients—they are permanently high-risk and require surveillance well beyond age 65 2, 3
Do not discontinue screening at 20 years if the patient is younger than 65-70 years old; continue annually, as recommended by the American College of Obstetricians and Gynecologists 2

Confirm through pathology reports that the hysterectomy was performed for adenocarcinoma in situ, and document the date of hysterectomy to track the 20-25 year surveillance period, as recommended by the American College of Obstetricians and Gynecologists 2, 3

Consider combining high-risk HPV testing with vaginal cytology, as this combination significantly increases detection of vaginal intraepithelial neoplasia and recurrence compared to cytology alone, as recommended by the American College of Obstetricians and Gynecologists 2